Dual GIP/GLP-1 Receptor Agonist
Tirzepatide
A synthetic 39-amino acid dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Research examines its synergistic effects on glucose homeostasis, insulin sensitivity, adipose tissue reduction, and metabolic syndrome markers.
Certificate of Analysis
COA Processing
A COA is not currently posted for this product. If documentation becomes available, it will be listed here and in the COA database.
Storage Requirements
Stability Information
Research Overview
Tirzepatide in Research
A synthetic 39-amino acid dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Research examines its synergistic effects on glucose homeostasis, insulin sensitivity, adipose tissue reduction, and metabolic syndrome markers.
Important Research Notice
Not for human consumption.
This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations. View full disclaimer